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Abstract
Background: For decades, it has been hypothesized that reproductive tract infections (RTIs) are risk factors for
uterine fibroids. However, only two recent studies have been conducted. We aimed to investigate the rela-
tionship between RTIs and fibroids in a large study using ultrasound screening for fibroids.
Methods: We used cross-sectional enrollment data from African American women ages 23–34 years with no
previous fibroid diagnosis. RTI history was measured by self-report and fibroid status by standardized ultra-
sound. Secondary fibroid outcomes were size, number, and total volume. Age- and multivariable-adjusted
logistic regression were used to estimate odds ratios (ORs).
Results: In total, 1,656 women were included; 22% had fibroids. Bacterial vaginosis (BV) was associated with a
21% increased odds of fibroids [aOR 1.21, 95% confidence interval (CI) 0.93–1.58]. Chlamydia infection and
pelvic inflammatory disease were associated with a 38% (aOR 0.62, 95% CI 0.40–0.97) and a 46% (aOR 0.54,
95% CI 0.25–1.17) reduced odds of having two or more fibroids, respectively. Those with a previous BV
diagnosis had a 47% increased odds of having 2 or more fibroids (aOR 1.47, 95% CI 0.98–2.21) and a 41%
increased odds of having a larger total fibroid volume (aOR 1.41, 95% CI 0.98–2.04).
Conclusions: Our study was the first to explore the relationship between RTIs and fibroid size, number, and
total volume. There appeared to be no strong associations between self-reported RTIs and fibroids. Studies
using serology, a biochemical measure of past infection, are needed to better investigate associations between
RTIs and fibroids.
Introduction
Uterine fibroids, benign, smooth-muscle-cell tumors ofthe uterus, are one of the most common gynecologic
conditions affecting women during their reproductive years.1
By age 50 years, the estimated risk of developing fibroids is
> 80% for African American women and close to 70% for
white women.2 The majority of women with fibroids are
asymptomatic; however, an estimated 20%–50% of women
experience symptoms (i.e., pelvic pain and pressure, severe
bleeding, and reproductive problems).1,3–5 The primary
treatment for fibroids is hysterectomy, and they are the
leading indication in the United States, accounting for 40% of
all procedures. The total estimated costs of fibroids in the
U.S. are as much as $34 billion annually.6
Although fibroids are responsible for substantial morbidity
and public health burden, their pathogenesis and etiology are
largely unknown. Fibroids are hormonally responsive;7 they
develop after menarche8 and tend to regress after menopause.9
However, what causes the initial transformation of muscle
cells into abnormal muscle cells and then their proliferation
and growth into clinically visible tumors is not understood.
Risk factors that have been established for fibroids are
African American heritage (African Americans are two to
three times as likely to have clinically recognized fibroids as
white women),6 older age (up to the age of menopause),
younger age at menarche, and nulliparity.10–13 Other factors
such as body mass index (BMI), smoking, and hormonal
contraceptive use have been inconsistently associated with
fibroid risk.10,14,15 More recent studies have shown no asso-
ciation with fibroids and smoking.15 Two studies have re-
ported that progestin-only injectables (i.e., Depo-Provera)
may be protective.11,16 Alcohol use may be a risk factor, but
the number of studies is small.15,17
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In the 1930s, Witherspoon18 hypothesized that reproduc-
tive tract infections (RTIs) play an etiological role in fibroid
development. Both RTIs and fibroids disproportionately
burden African American women and certain RTIs can lead
to conditions (i.e., chronic pelvic infection) that could result
in inflammatory reactions. Rates of reportable RTIs (i.e.,
chlamydia and gonorrhea) are 6 and 14 times as high among
African American women compared with white women, re-
spectively.19 In addition, rates of chlamydia and gonorrhea
are highest among younger women ages 15–24 years which
is, in most cases, the period before the diagnosis of fibroids.20
This hypothesis is consistent with another theorized mecha-
nism of fibroid pathogenesis involving tissue damage and
aberrant tissue repair/regeneration (increased extracellular
matrix, cell proliferation, and decreased apoptosis), leading
to the formation and growth of uterine fibroids.21,22
Yet, very few studies have investigated the effect of RTIs
on fibroid development. The two recently published studies
have only partially consistent results.10,23 The first was a
clinic-based case-control study of fibroid risk factors in the
Baltimore metropolitan area with fibroids confirmed by his-
tology or ultrasound.23 A positive dose–response association
was observed between the number of self-reported pelvic
inflammatory disease (PID) episodes and uterine fibroids.
No association was found between self-reported history of
genital herpes or warts and fibroids, although there was a
suggestion of an increased odds of fibroids for women with
self-reported history of chlamydia.23
The Uterine Fibroid Study (UFS)10 was a cross-sectional
study of randomly selected members of an urban health plan
screened for fibroids with ultrasound. No association of fi-
broids was found with self-reported diagnosis of PID. How-
ever, there were suggestions of positive associations with
self-reported history of chlamydia in white women, and with
trichomonas, syphilis, and ‘‘other infections’’ (mainly bac-
terial vaginosis [BV]) in African American women. Self-
reported history of genital herpes had nonsignificant elevated
odds ratios (ORs) in both ethnic groups.10 In both studies,10,23
self-reported history of abnormal Pap smear was inversely
associated with fibroids. This finding was also corroborated
in our recent study that showed an inverse association be-
tween self-reported cervical treatment and fibroids.24
A small study of 20 UFS participants examined fibroid
tissue for evidence of herpes simplex virus 1 and 2; cyto-
megalovirus; human herpesvirus 6, 7, and 8; Epstein-Barr
virus; and chlamydia10 using polymerase chain reaction and
histology. They did not detect any evidence of these patho-
gens in the tumor samples.
The goal of this study was to further investigate the rela-
tionship between self-reported RTIs and fibroids in a large
study of African American women with ultrasound screening
for fibroids. We also explored the relationship between self-
reported RTIs and number, size, and total volume of fibroids,
which has not previously been done.
Materials and Methods
We used transvaginal ultrasound results and self-reported
questionnaire data from participants in the ongoing National
Institute of Environmental Health Sciences (NIEHS) Study
of Environment, Lifestyle, and Fibroids (SELF) based in the
Detroit area. We used cross-sectional enrollment data with
history of RTIs measured by self-report as the exposures of
interest. Fibroid status measured by ultrasound at enrollment
was the outcome. Secondary outcomes were size of the
largest fibroid, number of fibroids, and total fibroid volume.
Study participants and data collection
SELF is a prospective cohort study of fibroid development.
Enrollment and data collection have been described previ-
ously.24 In brief, from November 2010 to December 2012,
the study enrolled a volunteer sample of 1,696 African
American women ages 23–34 without a prior diagnosis of
fibroids in the Detroit, Michigan area. Women were not eli-
gible for SELF if they had previously been diagnosed with
uterine fibroids; had a hysterectomy; had ever taken medi-
cation to treat lupus, Grave’s disease, Sjogren’s scleroderma,
or multiple sclerosis; or ever had any type of cancer treated
with radiation or chemotherapy.
During 2010–2012, recruitment materials, primarily com-
posed of targeted letters, media announcements, and flyers,
were distributed throughout the Detroit area with the aim of
informing the target population about the study. Interested
volunteers called the study number and began the enrollment
process including an orientation that thoroughly described
study activities. Those that completed all enrollment ques-
tionnaires and a clinic visit with ultrasound were enrolled.
Participants gave written informed consent. The study was
approved by the institutional review boards of NIEHS and
Henry Ford Health System (HFHS), a large medical provider
in the Detroit area and a collaborating institution.
Fibroid assessment
Transvaginal ultrasound is the standard procedure for the
detection and diagnosis of fibroids.25 It is as accurate as
magnetic resonance imaging for women with no more than
four fibroids.25 Fibroids were assessed by study sonographers
as described previously26 at one of three HFHS clinics. Focal
fibroids of 0.5 cm diameter or greater were measured in trip-
licate. For each measurement, the three perpendicular diame-
ters (longitudinal [L], anterior–posterior [A] and transverse
[T]) were recorded.
Outcome definitions
The primary outcome of this study was fibroid presence
(yes/no) at the transvaginal ultrasound examination com-
pleted at enrollment. Questionable fibroids were those for
which at least 1 diameter could not be measured. Participants
who had at least one fibroid or questionable fibroid ‡ 0.5 cm
at enrollment ultrasound (22%; n = 377) were considered to
have fibroids, and all women who did not have a fibroid or
questionable fibroid ‡ 0.5 cm in diameter at enrollment ul-
trasound (n = 1,319) were considered to not have fibroids.
The secondary outcomes were size of the largest fibroid,
number of fibroids, and total fibroid volume. The size of the
largest fibroid was determined by averaging the maximum
diameter (L, A, or T) of each of the triplicate fibroid mea-
surements. Fibroid volume (cm3) was measured by comput-
ing the volumes of each of the triplicate fibroid measurements
using the ellipsoid formula (L · A · T · 0.5233), and aver-
aging across the three volumes. Total fibroid volume (cm3)
was calculated by adding the average volumes from each of a
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woman’s fibroids. Total fibroid volume was not computed for
women with only questionable fibroids (n = 6) because at
least 1 diameter was not measured.
Reproductive tract infection assessment
At enrollment, SELF participants responded to ques-
tions regarding their history of RTIs via a self-administered
computer-assisted web interviewing (CAWI) questionnaire.
Each question on the CAWI required an answer before
the next question was presented. If no answer was recorded,
the same question was presented again, but an additional
response category was offered: ‘‘prefer not to answer.’’
The questions of interest used for this study were: (1) Has a
doctor or other health professional ever told you that you had
.? (2) How old were you when you were first diagnosed with
.? (3) In total, how many times have you been diagnosed
with .? These questions were asked for PID, chlamydia,
bacterial vaginosis, gonorrhea, trichomonas, genital herpes,
and genital warts.
For each RTI, those exposed were the women who re-
ported ‘‘Yes’’ to ever being diagnosed with that particular
RTI. The unexposed were those who reported ‘‘No’’ to ever
being diagnosed with that particular RTI. We also created a
variable, ‘‘any RTI,’’ representing whether the participant
had been diagnosed with any of the aforementioned RTIs.
The exposed group included those who self-reported at least
one RTI diagnosis, and the unexposed group comprised those
who did not self-report any RTI diagnosis. Two participants
were not included because they responded ‘‘prefer not to
answer’’ for at least one RTI and reported ‘‘no’’ for other
RTIs; thus, we could not determine their ‘‘any RTI’’ status.
Statistical analyses
Because the majority of questions were asked via tele-
phone or web-based interview where participants had to re-
spond to a question before proceeding, there was minimal
missing data. Any ‘‘prefer not to answer’’ response (0.06%–
0.12%) was coded as missing, and complete case analysis
was performed. Variables were categorized based on the
distribution of the data and comparability with the literature.
All analyses were completed on women who reported ever
being sexually active and who did not self-report a diagnosis of
human immunodeficiency virus (HIV) or use of HIV medi-
cations. Standard descriptive statistics were performed for all
variables of interest. For categorical variables, proportions at
each level were described. For continuous variables, medians
(interquartile ranges) were computed. Although sexual be-
havior variables are not confounders, we described the rela-
tionship between each RTI and number of sexual partners and
age at first intercourse for comparison with the literature. All
analyses were conducted with SAS 9.3.
Primary analyses: Association between RTIs
and fibroid presence
Logistic regression models were used to compute ORs and
95% confidence intervals (CIs) to evaluate the associations
between the self-reported RTI-related variables (PID, chla-
mydia, gonorrhea, trichomonas, BV, genital herpes, and gen-
ital warts) and fibroid presence. Because fibroids are common,
the relative odds will overestimate the relative risk, but it
provides a valid method of testing for statistically significant
differences between those with and without a self-reported
RTI diagnosis. Potential confounders were determined based
on a review of the literature and a directed acyclic graph and
were included in the full model: age in years (continuous); age
at menarche (7–10, 11–19 years); parity (nulliparous, parous);
education (high school/general education development (GED)
or less, some college/associates/technical, bachelors/masters/
doctorate); body mass index (BMI) (15–24, 25–29, 30–34,
‡ 35) in kg/m2; alcohol (low, moderate, heavy); and use of
Depo-Provera (ever, never). The alcohol variable reflected the
drinking level each woman reported for the age(s) when she
was drinking the most. Low drinkers were those who never had
10 or more drinks in a year. Heavy drinkers were those who
usually drank 6 or more drinks on days when they drank or
drank 4 + drinks per sitting at least 2–3 times a month. Mod-
erate drinkers were all others.
We evaluated the association of ‘‘any RTI’’ and each
self-reported RTI with fibroids in both age- and multivariable-
adjusted models. To control for confounding of an RTI–fibroid
association by another RTI, all RTIs were included in the
multivariable-adjusted model together [with the exception of
PID, which was modeled separately because it can share
causal pathways with other RTIs (e.g., chlamydia can cause
PID, so only the proximate factor, PID, would be included in
a model investigating effects of PID)]. Spearman partial
correlations (adjusted for age) among the other RTIs were
assessed to assure they were not highly correlated (Supple-
mentary Table S1; Supplementary Data are available online
at www.liebertpub.com/jwh).
Secondary analyses
As a secondary analysis we examined the association be-
tween RTIs and three outcomes: size of the largest fibroid,
number of fibroids, and total fibroid volume. Medians roun-
ded to the nearest whole number were used to determine
category cutpoints for size of the largest fibroid and total
fibroid volume (2cm and 2cm3, respectively). To estimate the
ORs and 95% CIs for the association of ‘‘any RTI’’ and each
RTI and fibroids, we used multinomial logistic regression
with the same potential confounders as in the primary anal-
ysis. All RTIs were included in the models together (with the
exception of PID, which was modeled separately).
As a secondary analysis to examine the association be-
tween RTI exposure severity and fibroid presence, we eval-
uated age- and multivariable-adjusted ORs of the association
between the number of times diagnosed with each RTI and
the presence of fibroids using two indicator variables (1 vs.
none; 2 + vs. none). Because of limited numbers of women
reporting multiple infections, each separate RTI was modeled
without adjusting for other RTIs. In addition, we looked at
whether self-reporting more than one type of infection in-
creased the odds of fibroids using three indicator variables
(1 vs. none; 2 vs. none; 3 + vs. none).
Sensitivity analyses
Syphilis was reported by too few women to analyze sep-
arately (n = 15), but we repeated the primary analyses after
excluding them to make sure they were not influential. Cer-
vical treatment is an indicator of cervical lesions secondary to
persistent HPV infection and was found to be inversely
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associated with fibroids in our previous study.24 Thus, the
RTI associations we were investigating might be attenuated.
Therefore, we repeated the primary analyses after excluding
those who reported cervical treatment (n = 229).
Results
Of the 1,696 women enrolled, 40 were excluded (34 re-
ported never having sex and 6 reported having HIV). Seventy
percent of participants reported at least one RTI diagnosis
(Table 1). Those with a prior history of an RTI, compared
with women without one, tended to be older, more educated,
heavier drinkers, parous, to have ever used Depo-Provera, to
have more sex partners before age 20 years, and to have been
younger at first sex (Table 1). The prevalences of specific
self-reported RTI diagnoses were: 10% for PID, 38% for
chlamydia and BV, 32% for trichomonas, 20% for gonorrhea,
9% for genital herpes, and 7% for genital warts (Supple-
mentary Table S2). The median time since first diagnosis of
any RTI was 9 years (interquartile range: 5–13 years) (Sup-
plementary Table S3).
Twenty-two percent (22%) of women had fibroids dis-
covered at ultrasound screening (Table 2). Of those with fi-
broids, the size of the largest fibroid was < 2 cm for 62%;
63% had only one fibroid. The total fibroid volume was
< 2cm3 for 52% of participants with fibroids.
In primary analyses, age-adjusted and multivariable ad-
justed estimates were very similar (Table 2). Self-reported
BV had a positive association with fibroids though not sig-
nificant (aOR 1.21, 95% CI 0.93–1.58). In secondary analy-
ses, we examined size of the largest fibroid, number of
fibroids and total fibroid volume as the outcomes (Fig. 1).
Women who reported any RTI had an elevated odds of a
small fibroid (aOR 1.31, 95% CI 0.93–1.84). There was a
38% reduction in the odds of having two or more fibroids for
chlamydia (aOR 0.62, 95% CI 0.40–0.97) and a 46% re-
duction for PID (aOR 0.54, 95% CI 0.25–1.17). Those with a
previous diagnosis of BV had a 47% increase in the odds of
having two or more fibroids (aOR 1.47, 95% CI 0.98–2.21)
and a 41% increase in the odds of having a larger total fibroid
volume ( ‡ 2cm3) (aOR 1.41, 95% CI 0.98–2.04).
In the secondary analyses that examined ‘‘severity’’ of RTI
based on number of different RTIs we saw an increase in odds
of fibroids for those with two RTIs (aOR 1.41, 95% CI 0.99–
2.01), but the odds was not elevated for those with three or
more RTIs (Supplementary Table S4). Multiple diagnoses of
the same RTI were not associated with higher odds of fibroids
(Supplementary Table S4).
The first sensitivity analysis, exclusion of those with a self-
reported diagnosis of syphilis (n = 15), resulted in little change
in associations between RTIs and fibroid presence (data not
shown). However, the second sensitivity analysis, removal of
those with a self-reported diagnosis of cervical treatment
(n = 229), resulted in a somewhat stronger association for
genital warts (aOR 1.29, 95% CI 0.76–2.18). Other RTI as-
sociations were essentially unchanged (data not shown).
Discussion
In this large study of young African American women,
there was little overall support for an association between
women’s self-reported histories of RTIs and subsequent fi-
broid development. Even those having a history of three or
more different RTIs or multiple diagnoses of the same RTI
showed no indication of elevated odds of fibroids. However,
our results for BV and chlamydia are suggestive of possible
associations with fibroids. Women reporting a history of BV
had somewhat elevated odds of both small and large fibroids.
Table 1. Distribution of Covariates by Self-




(N = 1,172) (N = 482)
Covariate n (%) n (%)
Age
23–26 343 (29) 157 (33)
27–30 396 (34) 170 (35)
‡ 31 433 (37) 155 (32)
Education
£ High school/GED 229 (20) 133 (28)
Some college or technical 639 (55) 201 (42)
‡ Bachelors 303 (26) 148 (31)
Missing 1
BMI (kg/m2)
15–24 212 (18) 111 (23)
25–29 266 (23) 78 (16)
30–34 236 (20) 84 (17)
‡ 35 458 (39) 209 (43)
Alcohol at age when drinking the mostb
Low 255 (22) 172 (36)
Moderate 386 (33) 157 (33)
Heavy 531 (45) 153 (32)
Parity
Nulliparous 409 (35) 218 (45)
Parous 763 (65) 264 (55)
Depo-Provera
Never used 638 (54) 300 (62)
Ever used 534 (46) 182 (38)
Age at menarche (years)
7–10 206 (18) 96 (20)
11–19 966 (82) 386 (80)
Sex partners before age 20 years
£ 1 203 (17) 190 (39)
2–5 588 (50) 237 (49)
‡ 6 379 (32) 55 (11)
Missing 2
Age at first sex (years)
£ 14 407 (35) 83 (17)
15–16 426 (36) 143 (30)
‡ 17 338 (29) 254 (53)
Missing 1 2
Any ‘‘prefer not to answer’’ response was coded as missing.
aIncludes pelvic inflammatory disease, chlamydia, bacterial
vaginosis, trichomonas, gonorrhea, genital herpes, and genital
warts. Two participants were not included because they responded
‘‘prefer not to answer’’ for at least one RTI and reported ‘‘no’’ for
other RTIs; thus, their ‘‘any RTI’’ status could not be determined.
bLow drinkers were those who never had 10 or more drinks in a
year. Heavy drinkers were those who usually drank 6 or more drinks
on days when they drank or drank 4 + drinks per sitting at least 2 to
3 times a month. Moderate drinkers were all others.
BMI, body mass index; GED, general education degree; IQR,
interquartile range.
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Table 2. Adjusted Odds Ratios for Fibroids According to Self-Reported History
of Reproductive Tract Infections
Fibroids
Age-adjusted Multivariable-adjustedYes No
N = 363 N = 1,293
Reproductive tract infections n (%) n (%) OR (95% CI) OR (95% CI)
Any RTIa
Yes 262 (72) 910 (70) 1.05 (0.80–1.36) 1.15 (0.87–1.52)b
No 101 (28) 381 (30)
Missing 2
PID
Yes 34 (9) 128 (10) 0.90 (0.60–1.35) 0.94 (0.62–1.43)b
No 329 (91) 1,164 (90)
Missing 1
Chlamydia
Yes 125 (34) 503 (39) 0.85 (0.66–1.09) 0.92 (0.70–1.21)c
No 238 (66) 788 (61)
Missing 2
Bacterial vaginosis
Yes 147 (41) 477 (37) 1.14 (0.89–1.45) 1.21 (0.93–1.58)c
No 216 (60) 815 (63)
Missing 1
Trichomonas
Yes 116 (32) 414 (32) 0.90 (0.70–1.16) 0.90 (0.68–1.20)c
No 247 (68) 878 (68)
Missing 1
Gonorrhea
Yes 62 (17) 261 (20) 0.81 (0.60–1.11) 0.94 (0.67–1.33)c
No 301 (83) 1,031 (80)
Missing 1
Genital herpes
Yes 31 (9) 112 (9) 0.93 (0.61–1.42) 0.89 (0.58–1.39)c
No 332 (91) 1,180 (91)
Missing 1
Genital warts
Yes 28 (8) 85 (7) 1.10 (0.70–1.73) 1.09 (0.68–1.74)c
No 335 (92) 1,207 (93)
Missing 1
Any ‘‘prefer not to answer’’ response was coded as missing.
aIncludes pelvic inflammatory disease, chlamydia, bacterial vaginosis, trichomonas, gonorrhea, genital herpes, and genital warts.
bLogistic regression model adjusted for age (continuous), education, body mass index, alcohol, menarche, parity, Depo–Provera use.
cLogistic regression model adjusted for age (continuous), education, body mass index, alcohol, menarche, parity, Depo–Provera use, and
other RTIs except PID and the RTI being evaluated.
CI, confidence interval; OR, odds ratio; PID, pelvic inflammatory disease; RTI, reproductive tract infection.
FIG. 1. Adjusted odds
ratios for size of the largest
fibroid, number of fibroids,
and total fibroid volume ac-
cording to self-reported his-
tory of reproductive tract
infections. aAdjusted for age,
education, body mass index,
alcohol, menarche, parity, and
Depo-Provera use. bAdjusted
for age, education, body mass
index, alcohol, menarche,
parity, Depo-Provera use, and
all other reproductive tract
infections (RTIs) except
pelvic inflammatory disease
and the RTI being evaluated.
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The associations were of borderline significance for two or
more fibroids and for larger total fibroid volume ( ‡ 2cm3).
Although speculative, the tendency for increased odds with
BV might be influenced by its chronic nature.27,28 For those
with a previous chlamydia diagnosis, the odds of having
multiple fibroids ( ‡ 2) was significantly reduced. However,
any mechanism for protection by chlamydia is unknown. In
summary, our study results do not corroborate any of the
suggestive increased odds of fibroids associated with self-
reported histories of PID, chlamydia, trichomonas, or herpes
previously described in smaller studies.10,23
This study has several limitations. It was a cross-sectional
analysis with self-reported RTI diagnoses. Though the onset
of fibroid development is unknown, over half of the women
reported their first RTI diagnosis before the age of 20, while
fibroid development in African Americans appears to be in-
frequent before the mid 20s.29 Also, most of the fibroids were
small suggesting relatively recent development. Finally, the
median time between first RTI diagnosis and study enroll-
ment was 9 years, again supporting the likelihood that ex-
posure occurred before disease onset.
Self-reported data on history of RTI diagnosis may be
subject to recall error.30–33 However, the frequencies of RTIs
in our sample are generally similar to those reported in other
studies of African American women.34,35 Perhaps a more
important problem is that the majority of RTIs can often be
asymptomatic, so even those who have not had a previous
diagnosis may still have had or currently have an RTI. Some
women also may have been tested and were positive but never
received their results, did not understand them, or just did not
report them (due to confidentiality concerns or social desir-
ability bias). Because questions were asked via a self-admin-
istered CAWI questionnaire, social desirability bias should
have been reduced.36,37 The validity of our self-reported data is
supported by our observation that both lower age at first sex
and higher numbers of sex partners were associated with in-
creased reporting of infection. Finally, our sample is not a
representative population-based sample of women. However,
because it captures early fibroid development (most of the wo-
men with fibroids had small fibroids), our sample was a relevant
one for investigating the possible role of RTIs in the hypothesized
fibroid pathogenesis involving aberrant tissue repair.21,22
Our study has several strengths. We used enrollment data
from an ongoing prospective study with a standardized
measure of fibroid status based on systematic ultrasound
screening rather than fibroids clinically detected because of
symptoms. The number, diameter, and volume of the fibroids
were systematically measured, so we were able to examine
associations with these separate characteristics. Twenty-two
percent (22%) of our cohort of young African American
women had fibroids at ultrasound screening, a prevalence
which falls within the range of prior U.S. studies that con-
ducted ultrasound screening.2,10,29,38 Our sample size was
sufficient to provide good precision for the main hypotheses.
We also had extensive data to assess potential confounding,
very minimal missing data, and we conducted sensitivity
analyses to evaluate potential bias.
Conclusions
Overall, the studies of RTIs and fibroids, including ours,
reveal no strong associations. Our study was the first to look
at the relationship between RTIs and fibroid size, number and
total volume, but most studies have been limited by the use of
self-reported exposure histories of these often asymptomatic
infections. The small study that looked for pathogens in fi-
broid tissue did no serological assessment to biochemically
measure past exposure to infection.10 Future studies are
needed to take the next step and use serology to better in-
vestigate associations between RTIs and fibroids.
Acknowledgments
This research was supported by the Intramural Research
Program of the NIH, National Institute of Environmental
Health Sciences (10-E-N044). Funding also came from the
American Recovery and Reinvestment Act funds designated
for National Institute of Health research.
The authors thank Drs. Lauren Wilson and Grace Kissling
for review of an earlier draft of the manuscript. Dr. Christie
Barker-Cummings of Social and Scientific Systems in Re-
search Triangle Park, NC, managed the overall study data.
Dr. Ganesa Wegienka is the research collaborator at Henry
Ford Health System in Detroit, Tracy Cooper is the head
sonographer there, and Karen Bourgeois manages the study
staff there.
Author Disclosure Statement
No competing financial interests exist.
References
1. Stewart EA. Uterine fibroids. Lancet 2001;357:293–298.
2. Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM.
High cumulative incidence of uterine leiomyoma in black
and white women: Ultrasound evidence. Am J Obstet Gy-
necol 2003;188:100–107.
3. Pritts EA, Parker WH, Olive DL. Fibroids and infertility:
An updated systematic review of the evidence. Fertil Steril
2009;91:1215–1223.
4. Lippman SA, Warner M, Samuels S, Olive D, Vercellini P,
Eskenazi B. Uterine fibroids and gynecologic pain symp-
toms in a population-based study. Fertil Steril 2003;80:
1488–1494.
5. Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-
reported heavy bleeding associated with uterine leiomyo-
mata. Obstet Gynecol 2003;101:431–437.
6. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann
BJ, Segars JH. The estimated annual cost of uterine leio-
myomata in the United States. Am J Obstet Gynecol
2012;206:211.e211–219.
7. Marsh EE, Bulun SE. Steroid hormones and leiomyomas.
Obstet Gynecol Clin North Am 2006;33:59–67.
8. Wright KN, Laufer MR. Leiomyomas in adolescents. Fertil
Steril 2011;95:2434.e15–17.
9. Cramer SF, Patel A. The frequency of uterine leiomyomas.
Am J Clin Pathol 1990;94:435–438.
10. Laughlin SK, Schroeder JC, Baird DD. New directions in
the epidemiology of uterine fibroids. Semin Reprod Med
2010;28:204–217.
11. Wise LA, Palmer JR, Harlow BL, et al. Reproductive
factors, hormonal contraception, and risk of uterine leio-
myomata in African-American women: A prospective
study. Am J Epidemiol 2004;159:113–123.
12. Marshall LM, Spiegelman D, Goldman MB, et al. A pro-
spective study of reproductive factors and oral contraceptive
494 MOORE ET AL.
use in relation to the risk of uterine leiomyomata. Fertil
Steril 1998;70:432–439.
13. Edwards DV. Association of age at menarche with in-
creasing number of fibroids in a cohort of women who
underwent standardized ultrasound assessment. Am J Epi-
demiol 2013;178:426–433.
14. Marshall LM, Spiegelman D, Manson JE, et al. Risk of
uterine leiomyomata among premenopausal women in re-
lation to body size and cigarette smoking. Epidemiology
1998;9:511–517.
15. Wise LA, Palmer JR, Harlow BL, et al. Risk of uterine
leiomyomata in relation to tobacco, alcohol and caffeine
consumption in the Black Women’s Health Study. Hum
Reprod 2004;19:1746–1754.
16. Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M,
Vudhikamraksa N, Werawatakul Y. Protective effect of
depot-medroxyprogesterone acetate on surgically treated
uterine leiomyomas: a multicentre case—control study. Br
J Obstet Gynaecol 1996;103:909–914.
17. Nagata C, Nakamura K, Oba S, Hayashi M, Takeda N,
Yasuda K. Association of intakes of fat, dietary fibre, soya
isoflavones and alcohol with uterine fibroids in Japanese
women. Br J Nutr 2009;101:1427–1431.
18. Witherspoon JT, Butler VW. The etiology of uterine fi-
broids with special reference to the frequency of their oc-
currence in the Negro: A hypothesis. Surg Gynecol Obstet
1934;58:4.
19. Centers for Disease Control and Prevention. Sexually
transmitted disease surveillance 2012. Atlanta: U.S. De-
partment of Health and Human Services, 2013. Available at
www.cdc.gov/std/stats12/Surv2012.pdf Accessed July 30, 2014.
20. Centers for Disease Control and Prevention. Incidence,
prevalence, and cost of sexually transmitted infections in
the United States. Atlanta: U.S. Department of Health and
Human Services, 2013. Available at www.cdc.gov/std/stats/
STI-Estimates-Fact-Sheet-Feb-2013.pdf Accessed June 20,
2013.
21. Leppert PC, Catherino WH, Segars JH. A new hypothesis
about the origin of uterine fibroids based on gene expres-
sion profiling with microarrays. Am J Obstet Gynecol
2006;195:415–420.
22. Wegienka G. Are uterine leiomyoma a consequence of a
chronically inflammatory immune system? Med Hy-
potheses 2012;79:226–231.
23. Faerstein E, Szklo M, Rosenshein NB. Risk factors for
uterine leiomyoma: A practice-based case-control study. II.
Atherogenic risk factors and potential sources of uterine
irritation. Am J Epidemiol 2001;153:11–19.
24. Moore KR, Smith JS, Laughlin-Tommaso SK, Baird DD.
Cervical neoplasia-related factors and decreased prevalence
of uterine fibroids among a cohort of African American
women. Fertil Steril 2014;101:208–214.
25. Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen
F. Accuracy of magnetic resonance imaging and transva-
ginal ultrasonography in the diagnosis, mapping, and
measurement of uterine myomas. Am J Obstet Gynecol
2002;186:409–415.
26. Moshesh M, Peddada SD, Cooper T, Baird D. Intraobserver
variability in fibroid size measurements: Estimated effects on
assessing fibroid growth. J Ultrasound Med 2014;33:1217–
1224.
27. Bradshaw CS, Morton AN, Hocking J, et al. High recur-
rence rates of bacterial vaginosis over the course of 12
months after oral metronidazole therapy and factors asso-
ciated with recurrence. J Infect Dis 2006;193:1478–1486.
28. Marrazzo JM. Interpreting the epidemiology and natural
history of bacterial vaginosis: Are we still confused?
Anaerobe 2011;17:186–190.
29. Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann
KE. Prevalence of uterine leiomyomas in the first trimester
of pregnancy: an ultrasound-screening study. Obstet Gy-
necol 2009;113:630–635.
30. Brown JL, Sales JM, DiClemente RJ, et al. Predicting
discordance between self-reports of sexual behavior and
incident sexually transmitted infections with African
American female adolescents: Results from a 4-city study.
AIDS Behav 2012;16:1491–1500.
31. Harrington KF, DiClemente RJ, Wingood GM, et al. Va-
lidity of self-reported sexually transmitted diseases among
African American female adolescents participating in an
HIV/STD prevention intervention trial. Sex Transm Dis
2001;28:468–471.
32. Hong Y, Fang X, Zhou Y, Zhao R, Li X. Factors associated
with sexually transmitted infection underreporting among
female sex workers in China. J Womens Health 2011;20:129–
136.
33. Niccolai LM, Kershaw TS, Lewis JB, Cicchetti DV, Ethier
KA, Ickovics JR. Data collection for sexually transmitted
disease diagnoses: A comparison of self-report, medical
record reviews, and state health department reports. Ann
Epidemiol 2005;15:236–242.
34. Leichliter JS, Chandra A, Aral SO. Correlates of self-
reported pelvic inflammatory disease treatment in sexually
experienced reproductive-aged women in the United States,
1995 and 2006–2010. Sex Transm Dis 2013;40:413–418.
35. Peterman TA, Newman DR, Torrone E, Schmitt K, Shiver S.
Cumulative risk of chlamydial infection among young
women in Florida, 2000–2011. J Adolesc Health 2014;55:
241–246.
36. Metzger DS, Koblin B, Turner C, et al. Randomized con-
trolled trial of audio computer-assisted self-interviewing:
Utility and acceptability in longitudinal studies. Am J
Epidemiol 2000;152:99–106.
37. Tideman RL, Chen MY, Pitts MK, Ginige S, Slaney M,
Fairley CK. A randomised controlled trial comparing
computer-assisted with face-to-face sexual history taking in
a clinical setting. Sex Transm Infect 2007;83:52–56.
38. Marsh EE, Ekpo GE, Cardozo ER, Brocks M, Dune T,
Cohen LS. Racial differences in fibroid prevalence and
ultrasound findings in asymptomatic young women (18–30
years old): A pilot study. Fertil Steril 2013;99:1951–1957.
Address correspondence to:
Donna Day Baird, PhD
Epidemiology Branch A3-05
National Institute of Environmental Health Sciences
National Institutes of Health
PO Box 12233
Research Triangle Park, NC 27709
E-mail: baird@niehs.nih.gov
RTIS AND UTERINE FIBROIDS 495
